Benzodiazepine derivatives as RSV inhibitors
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
1. A compound represented by the formula
or a pharmaceutically acceptable salt thereof, wherein
R 4 is
and R 4 is substituted with at least one substituent selected from the group consisting of CH 3 , CN, fluoro, chloro, CH 3 O—, CH 3 C(O)—, CH 3 OCH 2 —, CH 3 OCH 2 CH 2 O—, —CF 3 , CF 3 O—
2. The compound of claim 1 , wherein R 4 is substituted with at least one group selected from —CH 3 , —CF 3 ,
3. The compound of claim 1 , wherein R 4 is substituted with two substituents, wherein each substituent is independently selected from CH 3 , CN, fluoro, chloro, CH 3 O—, CH 3 C(O)—, CH 3 OCH 2 -, CH 3 OCH 2 CH 2 O—, —CF 3 , CF 3 O—
4. The compound of claim 3 , wherein one substituent is
5. The compound of claim 3 , wherein one substituent is —CF 3 or
6. The compound of claim 3 , wherein R 4 is
and is further substituted by one group selected from
7. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
8. A method of treating a respiratory syncytial virus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.
9. The method of claim 8 , wherein the subject is a human.